Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$17390.00
-220.00 (-1.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $3.0B · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$772.9B
P/E
48.4x
↑EV/EBITDA
50.3x
↑ROE
21.9%
↑Gross Margin
100.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+725.2%
FCF CAGR
—
FCF margin
20.8%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $53.39B · net income $15.78B · FCF $11.09B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $53.39B | $53.39B | $14.84B | $21.06B | $95.0M |
| Net Income | $15.78B | $15.78B | $-8.09B | $1.68B | $-14.43B |
| EBITDA | $14.26B | $14.26B | $-8.83B | $2.90B | $-13.33B |
| EPS | 359.00 | 359.00 | -61.75 | 72.75 | -6242.25 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | 23.6% | 23.6% | -32.3% | 10.6% | -15618.5% |
| Net Margin | 29.6% | 29.6% | -54.5% | 8.0% | -15191.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | -0.02 | -0.00 |
| Current Ratio | 9.48 | 9.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $11.09B | $11.09B | $-7.98B | $2.98B | $-17.54B |
| Returns | |||||
| ROE | 21.9% | 21.9% | -14.4% | -8.5% | 65.8% |
| Valuation | |||||
| P/E | 48.44 | 48.44 | — | — | — |
| EV/EBITDA | 50.31 | 50.31 | — | — | — |
| P/B | 10.61 | 10.61 | 2.29 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 259.8% | 259.8% | -29.5% | 22064.2% | — |
| EPS Growth | 681.4% | 681.4% | -184.9% | 101.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
62.6%
EPS terminal req.
$1543.07
Spread vs growth
618.8%
5Y implied EPS CAGR
39.1%
EPS terminal req.
$1867.12
Spread vs growth
642.3%
10Y implied EPS CAGR
23.7%
EPS terminal req.
$3007.01
Spread vs growth
657.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+228.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-61.75 → 359.00
Residual
+228.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.